No Data
Information on individual stocks.
Perseus <4882.T> rebounds sharply. The company has started selling the "anti-GPR87 antibody" as a new research antibody and reagent for disease research, as well as the research antibody reagent "anti-Exatecan antibody" for ADC (antibody-drug conjugate). FIXER <5129.T> has risen for three consecutive days. An agreement for capital and business collaboration has been signed with Talkable Medical (Shibuya, Tokyo). Moving forward, a full-scale entry into the medical DX (digital transformation) field will strengthen the business of Talkable Medical further.
Perseus has begun selling new research antibodies and reagents.
On the 25th of last week, Perseus <4882.T> announced the launch of new research antibodies and reagents, "anti-GPR87 antibody" and "anti-Exatecan antibody". The "anti-GPR87 antibody" is being researched not only as a marker molecule for cancer discrimination but also as a target molecule for cancer treatment, and the company sells it as a research antibody reagent. The "anti-Exatecan antibody" is attracting attention as a next-generation cancer treatment drug and is offered as a research antibody reagent for ADC (antibody-drug conjugate).
Express News | [Large Shareholding Report] SBI Securities reported a shareholding of 6.88% in Perseus Proteomics (4882.JP).
Perseus and Tokyo University of Science are conducting joint research on antibody drug discovery using Machinery learning.
On the 18th of last week, Perseus <4882.T> announced the start of a joint research project with Tokyo University of Science on antibody drug discovery using Machinery learning. This joint research aims to quickly select the desired antibodies by combining the computational science analysis techniques of Professor Masashi Oue from the School of Computer Science and Engineering at Tokyo University of Science with the company's unique antibody library. The closing price on the 18th of last week was 398 yen, an increase of 18 yen compared to the previous day. Provided by Wealth Advisor Co.
With a soft tone, it is easy to sell for profit-taking, but a firm trend at lower prices is expected.
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to show a soft trend. The US Stock market was closed last weekend, leaving today's Tokyo market with little guidance. However, the Tokyo Stock Exchange Growth Market Index saw a significant rise for two consecutive days until last weekend, reaching a two-day increase of 5.84%, so today's Emerging Markets are likely to see profit-taking Sell and selling in anticipation of a rebound. Additionally, concerns over escalating US-China tensions and the uncertainty of the Trump administration's tariff policy continue to weigh on stock prices.
Perseus is ranked, and the performance forecast for the fiscal year ending March 2025 continues to provide clues.
Perseus <4882> has ranked (as of 9:32 AM). It has significantly continued to fall. After trading began on March 31, the previously undecided financial estimates for the fiscal year ending March 2025 were disclosed, and yesterday it hit the daily limit down. It seems that selling continues to be a factor today as well. The operating loss is estimated at 0.843 billion yen. The previous period had a loss of 0.894 billion yen. The pipeline activities for PPMX-T002 and PPMX-T003, etc. are ongoing, but as of now, there have been no leads to derivation. Volume change rate top [4
